Literature DB >> 24649173

Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach.

Hanna Björkelund1, Lars Gedda2, Magnus Malmqvist3, Karl Andersson3.   

Abstract

Overexpression and aberrant activity of the epidermal growth factor (EGF) have been observed in various cancer types, rendering it an important target in oncology research. The interaction between EGF and its receptor (EGFR), as well as subsequent internalization, is complex and may be affected by various factors including tyrosine kinase inhibitors (TKIs). By combining real-time binding curves produced in LigandTracer® with internalization assays conducted at different temperatures and with different TKIs, the processes of ligand binding, internalization and excretion was visualized. SKOV3 cells had a slower excretion rate compared to A431 and U343 cells, and the tested TKIs (gefitinib, lapatinib, AG1478 and erlotinib) reduced the degree of internalization. The kinetic analysis of the binding curves further demonstrated TKI-dependent balances of EGFR monomer and dimer populations, where lapatinib promoted the monomeric form, while the other TKIs induced dimers. The dimer levels were found to be associated with the apparent affinity of the EGF-EGFR interaction, with EGF binding stronger to EGFR dimers compared to monomers. This study analyzed how real-time molecular interaction analysis may be utilized in combination with perturbations in order to understand the kinetics of a ligand-receptor interaction, as well as some of its associated intracellular processes. Our multiple-temperature and -inhibitor assay setup renders it possible to follow the EGFR monomer, dimer and internalized populations in a detailed manner, allowing for a new perspective of the EGFR biology.

Entities:  

Keywords:  dimerization; epidermal growth factor; heterogeneity; internalization; kinetics; tyrosine kinase inhibitors

Year:  2012        PMID: 24649173      PMCID: PMC3956273          DOI: 10.3892/mco.2012.37

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  48 in total

Review 1.  Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments.

Authors:  Fabrício F T Barros; Desmond G Powe; Ian O Ellis; Andrew R Green
Journal:  Histopathology       Date:  2010-04       Impact factor: 5.087

Review 2.  Oncogenic kinase signalling.

Authors:  P Blume-Jensen; T Hunter
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

3.  Automated, high-resolution cellular retention and uptake studies in vitro.

Authors:  Henrik Björke; Karl Andersson
Journal:  Appl Radiat Isot       Date:  2006-04-18       Impact factor: 1.513

4.  Targeting tyrosine kinases in cancer: the second wave.

Authors:  Jose Baselga
Journal:  Science       Date:  2006-05-26       Impact factor: 47.728

5.  Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.

Authors:  R B Lichtner; A Menrad; A Sommer; U Klar; M R Schneider
Journal:  Cancer Res       Date:  2001-08-01       Impact factor: 12.701

6.  HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation.

Authors:  Aliccia Bollig-Fischer; Michele Dziubinski; Alaina Boyer; Ramsi Haddad; Craig N Giroux; Stephen P Ethier
Journal:  Cancer Res       Date:  2010-08-24       Impact factor: 12.701

Review 7.  The epidermal growth factor receptor pathway: a model for targeted therapy.

Authors:  Maurizio Scaltriti; José Baselga
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

8.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Authors:  Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

9.  Comparing the epidermal growth factor interaction with four different cell lines: intriguing effects imply strong dependency of cellular context.

Authors:  Hanna Björkelund; Lars Gedda; Karl Andersson
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

10.  Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF.

Authors:  Hanna Björkelund; Lars Gedda; Pavel Barta; Magnus Malmqvist; Karl Andersson
Journal:  PLoS One       Date:  2011-09-12       Impact factor: 3.240

View more
  10 in total

1.  Cells use molecular working memory to navigate in changing chemoattractant fields.

Authors:  Akhilesh Nandan; Abhishek Das; Robert Lott; Aneta Koseska
Journal:  Elife       Date:  2022-06-06       Impact factor: 8.713

Review 2.  The complexities of PKCα signaling in cancer.

Authors:  Adrian R Black; Jennifer D Black
Journal:  Adv Biol Regul       Date:  2020-11-23

3.  Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors.

Authors:  Hadis Honarvar; Kristina Westerlund; Mohamed Altai; Mattias Sandström; Anna Orlova; Vladimir Tolmachev; Amelie Eriksson Karlström
Journal:  Theranostics       Date:  2016-01-01       Impact factor: 11.556

4.  New approaches for the reliable in vitro assessment of binding affinity based on high-resolution real-time data acquisition of radioligand-receptor binding kinetics.

Authors:  Markus Zeilinger; Florian Pichler; Lukas Nics; Wolfgang Wadsak; Helmut Spreitzer; Marcus Hacker; Markus Mitterhauser
Journal:  EJNMMI Res       Date:  2017-03-07       Impact factor: 3.138

5.  Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.

Authors:  Anzhelika Vorobyeva; Olga Bragina; Mohamed Altai; Bogdan Mitran; Anna Orlova; Alexey Shulga; Galina Proshkina; Vladimir Chernov; Vladimir Tolmachev; Sergey Deyev
Journal:  Contrast Media Mol Imaging       Date:  2018-06-06       Impact factor: 3.161

6.  Differential effects of epidermal growth factor receptor inhibitors in a single patient with neuropathic pain.

Authors:  Marte Grønlie Cameron; Christian Kersten
Journal:  BMJ Case Rep       Date:  2021-03-26

7.  Bivalent EGFR-Targeting DARPin-MMAE Conjugates.

Authors:  Lennard Karsten; Nils Janson; Vadim Le Joncour; Sarfaraz Alam; Benjamin Müller; Jayendrakishore Tanjore Ramanathan; Pirjo Laakkonen; Norbert Sewald; Kristian M Müller
Journal:  Int J Mol Sci       Date:  2022-02-23       Impact factor: 5.923

8.  Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes.

Authors:  Neila Chekkat; Caterina M Lombardo; Cendrine Seguin; Marie-Charlotte Lechner; Florent Dufour; Yves Nominé; Marcella De Giorgi; Benoit Frisch; Olivier Micheau; Gilles Guichard; Danièle Altschuh; Sylvie Fournel
Journal:  Oncotarget       Date:  2018-02-17

9.  A conformational sensor based on genetic code expansion reveals an autocatalytic component in EGFR activation.

Authors:  Martin Baumdick; Márton Gelléri; Chayasith Uttamapinant; Václav Beránek; Jason W Chin; Philippe I H Bastiaens
Journal:  Nat Commun       Date:  2018-09-21       Impact factor: 14.919

10.  EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells.

Authors:  Nina Mallmann-Gottschalk; Yvonne Sax; Rainer Kimmig; Stephan Lang; Sven Brandau
Journal:  Int J Mol Sci       Date:  2019-09-22       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.